Abstract: Objective To observe the efficacy and safety of transcatheter arterial chemoembolization （TACE） combined with targeted therapy for advanced hepatocellular carcinoma. Methods From Jan. 2008,to Dec. 2012,60 cases of advanced hepatocellular carcinoma received TACE,among them,37 cases were treated with sorafenib after TACE,at a dose of 400 mg,twice a day（the dosage was adjusted according to the side effect）. Abdominal CT scans were regularly performed and treatment efficacy was evaluated according to the modified RECIST. The side effect of sorafenib was recorded,so was the liver function before and after TACE. Results In 37 patients received combined treatment（TACE plus sorafenib） and 23 patients received TACE alone,the median overall survival time were （13±0.98） months and （5±0.62） months,respectively （P=0.001）,the time to progression were （7.5±1.21） months and （5±0.62） months,respectively （P=0.001）,and at the end of followed-up,the disease control rate were 48.6% and 17.4% in the two groups,respectively（P<0.01）;The multivariate analysis showed that the risk factors for death were without combination of sorafenib and antiviral therapy,and the presence of portal vein tumor thrombus. The main side effect of sorafenib was hand-foot skin reaction. Conclusion TACE combined with sorafenib has prolonged time to disease progression and overall survival time in patients with advanced hepatocellular carcinoma with relatively good safety.

Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Sorafenib, Prognosis